Q-omics provides the consensus-scored ZMYND19 profile across patient tissues and cancer cell-line models. ZMYND19 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZMYND19 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, ZMYND19 RNA expression shows 18,909 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where ZMYND19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZMYND19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZMYND19 survival associations across molecular data types. ZMYND19 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZMYND19 RNA expression–survival associations across cancer types. High ZMYND19 expression shows unfavorable associations in ACC, KIRC, KIRP, MESO, LIHC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZMYND19 RNA expression.
This table summarizes ZMYND19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZMYND19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZMYND19 shows higher tumor expression in COAD, HNSC, BLCA, LUAD, STAD and LIHC. The COAD box plot shows higher ZMYND19 RNA expression in tumor versus normal tissue (log2 FC = +1.760, t-test p < 0.001).
This table shows molecular features associated with ZMYND19 in patient tissues and cancer cell lines. In patient samples, ZMYND19 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZMYND19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Lymphoma.
